Christopher Patusky Sells 2,910 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Patusky sold 2,910 shares of the business’s stock in a transaction on Friday, April 24th. The shares were sold at an average price of $569.00, for a total transaction of $1,655,790.00. Following the completion of the sale, the director directly owned 1,490 shares in the company, valued at $847,810. This represents a 66.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Christopher Patusky also recently made the following trade(s):

• On Friday, April 17th, Christopher Patusky sold 1,000 shares of United Therapeutics stock. The shares were sold at an average price of $578.88, for a total transaction of $578,880.00.

United Therapeutics Stock Down 1.0%

UTHR traded down $5.69 during trading on Friday, hitting $567.16. The company had a trading volume of 264,756 shares, compared to its average volume of 491,071. The company has a market capitalization of $24.86 billion, a PE ratio of 20.33, a PEG ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $607.89. The firm’s 50-day moving average price is $534.64 and its 200 day moving average price is $493.24.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the business earned $6.19 EPS. The company’s revenue was up 7.4% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on UTHR shares. Morgan Stanley lifted their price target on shares of United Therapeutics from $471.00 to $519.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Finally, Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Ten research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Clearstead Advisors LLC increased its stake in shares of United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 23 shares during the last quarter. Independent Advisor Alliance increased its stake in shares of United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after purchasing an additional 27 shares during the last quarter. Bessemer Group Inc. increased its stake in shares of United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 28 shares during the last quarter. Florida Financial Advisors LLC increased its stake in shares of United Therapeutics by 5.4% during the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 28 shares during the last quarter. Finally, NDVR Inc. increased its stake in shares of United Therapeutics by 5.1% during the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.